Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy

Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy

Introduction: Hypertrophic cardiomyopathy (HCM) is a leading cause of lethal arrhythmias in the young. Although the arrhythmic substrate has been hypothesised to be amenable to late Na+ block with ranolazine, the specific mechanisms are not fully understood. Therefore, this study aimed to investigat...

Full description

Bibliographic Details
Main Authors:	James A. Coleman, Ruben Doste, Matteo Beltrami, Alessia Argirò, Raffaele Coppini, Iacopo Olivotto, Betty Raman, Alfonso Bueno-Orovio
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Pharmacology
Subjects:	hypertrophic cardiomyopathy ranolazine drug safety and efficacy arrhythmic risk modelling and simulation
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1379236/full

Similar Items

Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy
by: Coleman, JA, et al.
Published: (2024)

Microvascular Dysfunction in Hypertrophic Cardiomyopathy
by: Francesco Pelliccia, et al.
Published: (2022-11-01)

Genetic testing for hypertrophic cardiomyopathy: ongoing voyage from exploration to clinical exploitation
by: Iacopo Olivotto, et al.
Published: (2011-07-01)

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
by: Ahmad Masri, et al.
Published: (2022-05-01)

Impact of ranolazine on ventricular arrhythmias – A systematic review
by: George Bazoukis, et al.
Published: (2018-04-01)

Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy
by: Niccolò Maurizi, et al.
Published: (2023-04-01)

Arrhythmogenic Cardiomyopathy: Definition, Classification and Arrhythmic Risk Stratification
by: Marisa Varrenti, et al.
Published: (2024-01-01)

Compound Mutation in Cardiac Sarcomere Proteins Is Associated with Increased Risk for Major Arrhythmic Events in Pediatric Onset Hypertrophic Cardiomyopathy
by: Kathrin Pollmann, et al.
Published: (2021-11-01)

Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?
by: Francesco Mazzarotto, et al.
Published: (2020-04-01)

Emerging Medical Treatment for Hypertrophic Cardiomyopathy
by: Alessia Argirò, et al.
Published: (2021-03-01)

Hypertrophic Cardiomyopathy : A Practical Guide to Diagnosis and Management /
by: Adhyapak, Srilakshmi M., editor 635827, et al.
Published: (2021)

Apical Hypertrophic Cardiomyopathy: A Special Entity.
by: Ajay Adhikaree, et al.
Published: (2020-01-01)

Identifying Obstructive Hypertrophic Cardiomyopathy from Nonobstructive Hypertrophic Cardiomyopathy: Development and Validation of a Model Based on Electrocardiogram Features
by: Lanyan Guo, et al.
Published: (2023-08-01)

Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different TNNT2 Mutations
by: Josè Manuel Pioner, et al.
Published: (2022-04-01)

Hypertrophic cardiomyopathy
by: Sarita Gore, et al.
Published: (2022-01-01)

Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy
by: Francesco Santoro, et al.
Published: (2023-05-01)

Electrophysiological mechanisms underlying T wave pseudonormalisation on stress ECGs in hypertrophic cardiomyopathy
by: Coleman, J, et al.
Published: (2023)

Ranolazine: Multifaceted role beyond coronary artery disease, a recent perspective
by: Gopal Chandra Ghosh, et al.
Published: (2018-01-01)

Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy
by: Mark V. Sherrid, et al.
Published: (2021-10-01)

Tips for Successful Septal Myectomy in Patients with Hypertrophic Cardiomyopathy
by: Jae Hyun Kim
Published: (2018-06-01)

Cardiovascular magnetic resonance in hypertrophic cardiomyopathy and infiltrative cardiomyopathy
by: Rebecca Schofield, et al.
Published: (2016-11-01)

Hypertrophic Cardiomyopathy
by: Polakit Teekakirikul, MD, et al.
Published: (2021-09-01)

Update on evidence for treatment with ranolazine in stable angina
by: Federico Carbone, et al.
Published: (2013-10-01)

Clinical study of patients with hypertrophic cardiomyopathy
by: Amjad R. Bairam, et al.
Published: (2013-01-01)

Alternative Management Options for Hypertrophic Cardiomyopathy
by: Cristina Raimondo, MD, et al.
Published: (2020-03-01)

Editorial - 2014 European Society of Cardiology Guidelines on Hypertrophic Cardiomyopathy
by: Murat Özdemir
Published: (2014-12-01)

Facilitation of Insulin Effects by Ranolazine in Astrocytes in Primary Culture
by: Adrián Jordá, et al.
Published: (2022-10-01)

Remodelling of potassium currents underlies arrhythmic action potential prolongation under beta-adrenergic stimulation in hypertrophic cardiomyopathy
by: Doste, R, et al.
Published: (2022)

Ventricular Arrhythmia in Septal and Apical Hypertrophic Cardiomyopathy: The French-Canadian Experience
by: Christian Steinberg, et al.
Published: (2020-10-01)

Hypertrophic Cardiomyopathy in a Latin American Center: A Single Center Observational Study
by: Juan David López-Ponce de Leon, et al.
Published: (2023-08-01)

Primary Hypertrophic Cardiomyopathy in Children
by: N.V. Nagornaya, et al.
Published: (2013-02-01)

Hypertrophic cardiomyopathy masked by pericarditis
by: Larry Nichols, et al.
Published: (2019-10-01)

Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions
by: Francesca Girolami, et al.
Published: (2023-03-01)

A case of vasospastic angina. Vasospasm physiopathology: a new therapeutic role for ranolazine?
by: Carlo Uran, et al.
Published: (2020-08-01)

Distinct ECG Phenotypes Identified in Hypertrophic Cardiomyopathy Using Machine Learning Associate With Arrhythmic Risk Markers
by: Aurore Lyon, et al.
Published: (2018-03-01)

Ranolazine Inhibits Pyroptosis via Regulation of miR-135b in the Treatment of Diabetic Cardiac Fibrosis
by: Long Ren, et al.
Published: (2022-01-01)

Clinical presentation and long‐term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study
by: Gabrielle Norrish, et al.
Published: (2021-12-01)

Hypertrophic Cardiomyopathy After Heart Transplantation
by: Hans Gao, MD, et al.
Published: (2023-05-01)

INFECTIVE ENDOCARDITIS IN THE PRESENCE OF HYPERTROPHIC CARDIOMYOPATHY
by: E. Yu. Ponomareva
Published: (2014-07-01)

INFECTIVE ENDOCARDITIS IN THE PRESENCE OF HYPERTROPHIC CARDIOMYOPATHY
by: E. Yu. Ponomareva
Published: (2014-07-01)